{
  "ticker": "TGTX",
  "company_name": "TG Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02612311",
      "title": "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Chronic Lymphocytic Leukemia",
      "start_date": "2015-11-19",
      "completion_date": "2023-02-22",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07211633",
      "title": "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Relapsing Multiple Sclerosis",
      "start_date": "2025-07-09",
      "completion_date": "2028-12-31",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06433752",
      "title": "A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI\u00ae (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Relapsing Multiple Sclerosis, Multiple Sclerosis",
      "start_date": "2024-07-22",
      "completion_date": "2027-07-01",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02301156",
      "title": "Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Lymphocytic Leukemia",
      "start_date": "2015-01-27",
      "completion_date": "2020-04-01",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07225361",
      "title": "Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis",
      "status": "RECRUITING",
      "phase": "PHASE4",
      "condition": "Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting",
      "start_date": "2025-11-28",
      "completion_date": "2029-08-01",
      "enrollment": 0,
      "sponsor": "Northwestern University"
    },
    {
      "nct_id": "NCT03207256",
      "title": "Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma",
      "start_date": "2017-08-09",
      "completion_date": "2022-06-24",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03381170",
      "title": "An Extension of the TG1101-RMS201 Trial",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Relapsing Remitting Multiple Sclerosis",
      "start_date": "2017-06-01",
      "completion_date": "2022-11-11",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02268851",
      "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma",
      "start_date": "2014-11",
      "completion_date": "2022-10",
      "enrollment": 0,
      "sponsor": "Dana-Farber Cancer Institute"
    },
    {
      "nct_id": "NCT06433765",
      "title": "A Study Evaluating the Effect of BRIUMVI\u00ae (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Multiple Sclerosis",
      "start_date": "2024-06-01",
      "completion_date": "2035-03-31",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02738775",
      "title": "Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Multiple Sclerosis",
      "start_date": "2016-05-27",
      "completion_date": "2018-08-13",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 46,
    "by_phase": {
      "PHASE3": 7,
      "": 3,
      "PHASE4": 1,
      "PHASE2": 15,
      "PHASE1": 13,
      "PHASE1, PHASE2": 3,
      "NA": 1,
      "PHASE2, PHASE3": 3
    },
    "by_status": {
      "TERMINATED": 18,
      "RECRUITING": 7,
      "COMPLETED": 16,
      "NOT_YET_RECRUITING": 3,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 9,
    "completed_trials": 16,
    "conditions": [
      "Autoimmune Disorders",
      "B-Cell Lymphoma",
      "B-cell Mediated Autoimmune Disorders",
      "B-cell Non Hodgkin Lymphoma, Richter's Transformation",
      "CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL",
      "Chronic Lymphocytic Leukemia",
      "Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL",
      "Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma",
      "Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma",
      "Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma",
      "Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma",
      "Chronic Lymphocytic Leukemia, Richter Syndrome",
      "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
      "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia",
      "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma",
      "Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma",
      "Follicular Lymphoma",
      "Follicular Lymphoma, Small Lymphocytic Lymphoma",
      "Hodgkin's Lymphoma",
      "Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma Grade 2, Follicular Lymphoma Grade IIIa, Marginal Zone Lymphoma, Marginal Zone B Cell Lymphoma",
      "Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma",
      "Multiple Sclerosis",
      "Multiple Sclerosis (MS) - Relapsing-remitting",
      "Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting",
      "Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia",
      "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma",
      "Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma",
      "Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia",
      "Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST)",
      "Relapsing Multiple Sclerosis",
      "Relapsing Multiple Sclerosis (RMS)",
      "Relapsing Multiple Sclerosis, Multiple Sclerosis",
      "Relapsing Remitting Multiple Sclerosis"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:23.544702",
    "search_query": "TG Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=TG+Therapeutics,+Inc."
  }
}